Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Smolen

Showing results (1171-1180 of 1,467) with videos related to

Pageof 147
Sort By:
Annals of the Rheumatic Diseases|September 9, 2018
Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective studyTsutomu Takeuchi, Mark C Genovese, Boulos Haraoui, et al.
Annals of the Rheumatic Diseases|April 26, 2022
Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritisLotte van Ouwerkerk, Andriko Palmowski, Isabell S Nevins, et al.
Annals of the Rheumatic Diseases|April 15, 2004
EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritisC-S Yee, C Gordon, C Dostal, et al.
Arthritis and Rheumatism|March 2, 2006
Infliximab treatment maintains employability in patients with early rheumatoid arthritisJosef S Smolen, Chenglong Han, Désirée van der Heijde, et al.
Arthritis Research & Therapy|June 23, 2023
Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world studyLaure Gossec, Stefan Siebert, Paul Bergmans, et al.
Annals of the Rheumatic Diseases|January 4, 2023
Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world studyLaure Gossec, Stefan Siebert, Paul Bergmans, et al.
Genes & Development|November 11, 2010
A genome-wide RNAi screen identifies multiple RSK-dependent regulators of cell migrationGromoslaw A Smolen, Jianmin Zhang, Matthew J Zubrowski, et al.
Mbio|January 13, 2021
Biogeography of the Relationship between the Child Gut Microbiome and Innate Immune SystemNelly Amenyogbe, Pedro Dimitriu, Kinga K Smolen, et al.
Rheumatology (Oxford, England)|September 29, 2017
Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety resultsJosef S Smolen, Jung-Yoon Choe, Nenad Prodanovic, et al.
Annals of the Rheumatic Diseases|October 19, 2017
Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition studyJosef S Smolen, Jung-Yoon Choe, Nenad Prodanovic, et al.
Pageof 147

Showing results (1171-1180 of 1,467) with videos related to

Sort By:
Pageof 147
Annals of the Rheumatic Diseases|September 9, 2018
Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective studyTsutomu Takeuchi, Mark C Genovese, Boulos Haraoui, et al.
Annals of the Rheumatic Diseases|April 26, 2022
Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritisLotte van Ouwerkerk, Andriko Palmowski, Isabell S Nevins, et al.
Annals of the Rheumatic Diseases|April 15, 2004
EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritisC-S Yee, C Gordon, C Dostal, et al.
Arthritis and Rheumatism|March 2, 2006
Infliximab treatment maintains employability in patients with early rheumatoid arthritisJosef S Smolen, Chenglong Han, Désirée van der Heijde, et al.
Arthritis Research & Therapy|June 23, 2023
Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world studyLaure Gossec, Stefan Siebert, Paul Bergmans, et al.
Annals of the Rheumatic Diseases|January 4, 2023
Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world studyLaure Gossec, Stefan Siebert, Paul Bergmans, et al.
Genes & Development|November 11, 2010
A genome-wide RNAi screen identifies multiple RSK-dependent regulators of cell migrationGromoslaw A Smolen, Jianmin Zhang, Matthew J Zubrowski, et al.
Mbio|January 13, 2021
Biogeography of the Relationship between the Child Gut Microbiome and Innate Immune SystemNelly Amenyogbe, Pedro Dimitriu, Kinga K Smolen, et al.
Rheumatology (Oxford, England)|September 29, 2017
Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety resultsJosef S Smolen, Jung-Yoon Choe, Nenad Prodanovic, et al.
Annals of the Rheumatic Diseases|October 19, 2017
Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition studyJosef S Smolen, Jung-Yoon Choe, Nenad Prodanovic, et al.
Pageof 147